Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer- technology appraisal guidance (TA668)
NICE recommends encorafenib plus cetuximab, as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment only if the company provides it according to the commercial arrangements.
Source:
National Institute for Health and Care Excellence